Home LiteratureArticle Details
PMID: 12768015 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

Journal of virology ·Vol. 77 ·No. 12 ·2003-06-00 ·Pages 6965-78

Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV, Parren PW, Burton DR

Abstract

The V1/V2 and V3 loops are proximal to the CD4 binding site (CD4bs) of human immunodeficiency virus type 1 (HIV-1) gp120 and undergo conformational change upon CD4 receptor engagement by the HIV-1 envelope spike. Nearly all of the reported monoclonal antibodies (MAbs) against the CD4bs exhibit a very limited capacity to neutralize HIV-1. However, one such human MAb, immunoglobulin G1 (IgG1) b12, is uniquely able to neutralize primary isolates across subtypes with considerable potency. The molecular basis for the anti-HIV-1 activity of b12 is not fully understood but is relevant to vaccine design. Here we describe a novel human MAb, 4KG5, whose binding to monomeric gp120 is moderately enhanced by IgG1 b12. In sharp contrast, 4KG5 binding to gp120 is inhibited by soluble CD4 (sCD4) and by all other (n = 14) anti-CD4bs MAbs tested. 4KG5 is unable to recognize gp120 in which either V1, V2, or V3 has been deleted, and MAbs against the V2 or V3 loops inhibit the binding of 4KG5 to gp120. Moreover, 4KG5 is able to inhibit the binding of the CD4-induced MAbs 17b and X5 in the absence of sCD4, whereas 17b and X5 only weakly inhibit the binding of 4KG5 to gp120. Mutagenesis of gp120 provides further evidence of a discontinuous epitope of 4KG5 that is formed by the V1/V2 loop, the V3 loop, and a portion of the bridging sheet (C4). 4KG5 was isolated as a single-chain Fv from a phage display library constructed from the bone marrow of an HIV-1-seropositive subject (FDA2) whose serum neutralizes HIV-1 across subtypes. Despite its source, we observed no significant neutralization with 4KG5 against the autologous (R2) virus and several other strains of HIV-1. The results suggest a model in which antibody access to the CD4bs on the envelope spike of HIV-1 is restricted by the orientation and/or dynamics of the V1/V2 and V3 loops, and b12 avoids these restrictions.

MeSH Terms
Amino Acid Sequence Antibodies, Monoclonal/immunology Base Sequence Binding, Competitive Epitope Mapping Epitopes/immunology HIV Antibodies/immunology HIV Envelope Protein gp120/chemistry,immunology HIV-1/immunology Humans Immunoglobulin G/immunology Molecular Sequence Data Neutralization Tests Peptide Fragments/immunology
Chemicals
Antibodies, Monoclonal Epitopes HIV Antibodies HIV Envelope Protein gp120 HIV envelope protein gp120 (135-148) HIV envelope protein gp120 (305-321) Immunoglobulin G Peptide Fragments
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Zwick Michael B
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA.
Kelleher Robert
Jensen Richard
Labrijn Aran F
Wang Meng
Quinnan Gerald V
Parren Paul W H I
Burton Dennis R
References (95)
95 references, click to expand
  1. Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.
    J Virol. 2001 Aug;75(16):7785-8 PMID: 11462056
  2. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1067-76 PMID: 11485624
  3. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
    Science. 2001 Aug 10;293(5532):1155-9 PMID: 11498595
  4. Structural features of HIV envelope defined by antibody escape mutant analysis.
    AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1205-9 PMID: 11522189
  5. HIV gp120 V(1)/V(2) and C(2)-V(3) domains glycoprotein compatibility is required for viral replication.
    Virus Res. 2001 Nov 5;79(1-2):91-101 PMID: 11551649
  6. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    J Virol. 2001 Nov;75(22):10892-905 PMID: 11602729
  7. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.
    J Virol. 2001 Dec;75(24):12198-208 PMID: 11711611
  8. The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.
    Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15227-32 PMID: 11734627
  9. Mechanisms of viral membrane fusion and its inhibition.
    Annu Rev Biochem. 2001;70:777-810 PMID: 11395423
  10. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65 PMID: 11788027
  11. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.
    J Virol. 2002 Apr;76(8):3852-64 PMID: 11907225
  12. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
    Nat Rev Immunol. 2002 Apr;2(4):283-91 PMID: 12001999
  13. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8 PMID: 11997472
  14. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
    J Virol. 2002 Jul;76(14):7293-305 PMID: 12072528
  15. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    J Virol. 2002 Jul;76(14):7306-21 PMID: 12072529
  16. The HIV-1 vaccine race.
    Cell. 2002 Jul 26;110(2):135-8 PMID: 12150921
  17. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Nature. 2002 Dec 12;420(6916):678-82 PMID: 12478295
  18. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.
    J Virol. 1988 Nov;62(11):4195-200 PMID: 2845130
  19. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.
    J Virol. 1989 Sep;63(9):3579-85 PMID: 2474670
  20. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.
    Proc Natl Acad Sci U S A. 1990 Nov;87(21):8597-601 PMID: 1700435
  21. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    J Virol. 1991 Jan;65(1):489-93 PMID: 1702163
  22. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.
    J Virol. 1991 Nov;65(11):6188-93 PMID: 1717717
  23. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949-52 PMID: 1717992
  24. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    J Virol. 1992 Feb;66(2):848-56 PMID: 1370558
  25. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    J Virol. 1992 Sep;66(9):5635-41 PMID: 1380099
  26. Delineation of immunoreactive, conserved regions in the external glycoprotein of the human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 1992 Jun;8(6):1125-32 PMID: 1380259
  27. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.
    Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43 PMID: 1384050
  28. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
    J Virol. 1992 Dec;66(12):6997-7004 PMID: 1279195
  29. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.
    J Virol. 1992 Dec;66(12):7538-42 PMID: 1433529
  30. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  31. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
    J Virol. 1993 Aug;67(8):4557-65 PMID: 8331723
  32. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.
    Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30 PMID: 9210678
  33. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
    J Infect Dis. 1998 Feb;177(2):310-9 PMID: 9466516
  34. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.
    J Virol. 1998 May;72(5):3512-9 PMID: 9557629
  35. CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.
    Proc Natl Acad Sci U S A. 1998 May 12;95(10):5740-5 PMID: 9576954
  36. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
    Science. 1998 Jun 19;280(5371):1949-53 PMID: 9632396
  37. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  38. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
    J Virol. 1998 Aug;72(8):6332-8 PMID: 9658072
  39. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.
    J Virol. 1998 Oct;72(10):8437-45 PMID: 9733899
  40. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.
    J Virol. 1998 Nov;72(11):9384-91 PMID: 9765494
  41. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.
    J Virol. 1998 Dec;72(12):10270-4 PMID: 9811774
  42. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120.
    AIDS Res Hum Retroviruses. 1998 Nov 1;14(16):1451-6 PMID: 9824323
  43. Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1).
    J Biol Chem. 1999 Feb 12;274(7):4115-23 PMID: 9933605
  44. Recombinant human monoclonal antibodies to Ebola virus.
    J Infect Dis. 1999 Feb;179 Suppl 1:S235-9 PMID: 9988189
  45. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response.
    AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):561-70 PMID: 10221533
  46. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
    J Virol. 2002 Sep;76(17):8953-7 PMID: 12163614
  47. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    J Virol. 2002 Sep;76(18):9035-45 PMID: 12186887
  48. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    J Virol. 2002 Oct;76(19):9888-99 PMID: 12208966
  49. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
    J Virol. 2003 Jan;77(1):642-58 PMID: 12477867
  50. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
    J Virol. 1999 Jun;73(6):4640-50 PMID: 10233923
  51. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
    J Virol. 2000 Feb;74(4):1787-93 PMID: 10644351
  52. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.
    J Virol. 2000 Jun;74(11):5091-100 PMID: 10799583
  53. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120.
    AIDS Res Hum Retroviruses. 2000 May 20;16(8):741-9 PMID: 10826481
  54. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
    J Virol. 1993 Aug;67(8):4785-96 PMID: 7687303
  55. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  56. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    J Virol. 1994 Jan;68(1):469-84 PMID: 7504741
  57. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.
    J Virol. 1994 Apr;68(4):2253-9 PMID: 8139010
  58. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.
    J Virol. 1994 Jun;68(6):4001-8 PMID: 7514683
  59. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):4821-8 PMID: 7518527
  60. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.
    J Virol. 1994 Nov;68(11):6994-7000 PMID: 7933081
  61. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    J Virol. 1994 Dec;68(12):8350-64 PMID: 7525988
  62. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Science. 1994 Nov 11;266(5187):1024-7 PMID: 7973652
  63. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
    J Immunol. 1995 Jan 15;154(2):893-906 PMID: 7529290
  64. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.
    J Virol. 1995 Jun;69(6):3807-15 PMID: 7745728
  65. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
    J Exp Med. 1995 Jul 1;182(1):185-96 PMID: 7540648
  66. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  67. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
    J Virol. 1995 Oct;69(10):6191-8 PMID: 7545244
  68. Preparation and characterization of human HIV type 1 neutralizing reference sera.
    AIDS Res Hum Retroviruses. 1995 Jul;11(7):783-7 PMID: 7546904
  69. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
    J Virol. 1996 Jan;70(1):427-44 PMID: 8523556
  70. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.
    J Virol. 1996 Jan;70(1):445-58 PMID: 8523557
  71. A trimeric structural domain of the HIV-1 transmembrane glycoprotein.
    Nat Struct Biol. 1995 Dec;2(12):1075-82 PMID: 8846219
  72. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  73. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants.
    J Virol. 1996 Feb;70(2):1301-9 PMID: 8551600
  74. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells.
    J Virol. 1996 Feb;70(2):1310-6 PMID: 8551601
  75. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.
    J Virol. 1996 Mar;70(3):1863-72 PMID: 8627711
  76. The role of the humoral immune response in HIV infection.
    AIDS. 1996;10 Suppl A:S97-106 PMID: 8883616
  77. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):179-83 PMID: 8906795
  78. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):184-7 PMID: 8906796
  79. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
    Virology. 1996 Dec 15;226(2):217-27 PMID: 8955041
  80. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein.
    J Virol. 1997 Apr;71(4):2674-84 PMID: 9060620
  81. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    J Virol. 1997 May;71(5):3734-41 PMID: 9094648
  82. Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries.
    J Mol Biol. 1997 Apr 4;267(3):684-95 PMID: 9126846
  83. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.
    J Infect Dis. 1997 May;175(5):1056-62 PMID: 9129066
  84. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  85. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
    AIDS. 1999;13 Suppl A:S137-62 PMID: 10885772
  86. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.
    J Virol. 2000 Dec;74(23):11008-16 PMID: 11069996
  87. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.
    J Virol. 2000 Dec;74(24):11955-62 PMID: 11090196
  88. IMGT, the international ImMunoGeneTics database.
    Nucleic Acids Res. 2001 Jan 1;29(1):207-9 PMID: 11125093
  89. Virolysis and in vitro neutralization of HIV-1 by humanized monoclonal antibody hNM-01.
    Hybridoma. 2000 Dec;19(6):427-34 PMID: 11152394
  90. gp120: Biologic aspects of structural features.
    Annu Rev Immunol. 2001;19:253-74 PMID: 11244037
  91. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.
    J Biol Chem. 2001 Apr 20;276(16):13433-41 PMID: 11278567
  92. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.
    Biochemistry. 2001 Feb 13;40(6):1662-70 PMID: 11327825
  93. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
    J Virol. 2001 Jun;75(12):5457-64 PMID: 11356952
  94. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.
    J Virol. 2001 Jul;75(13):5721-9 PMID: 11390574
  95. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.
    J Virol. 2001 Jul;75(13):5998-6006 PMID: 11390601
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/jvi.77.12.6965-6978.2003
Published
2003-06-00
Pages
6965-78
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC156200
Subset
IM
Grants
NCRR NIH HHS · M01 RR000833 · United States
NIAID NIH HHS · AI40377 · United States
NCRR NIH HHS · M01 RR00833 · United States
NIAID NIH HHS · R37 AI033292 · United States
NIAID NIH HHS · R01 AI033292 · United States
NIAID NIH HHS · AI33292 · United States
NIAID NIH HHS · AI37438 · United States
NIAID NIH HHS · R21 AI037438 · United States
NIAID NIH HHS · R01 AI037438 · United States
External Links
PubMed source DOI: 10.1128/jvi.77.12.6965-6978.2003 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2